Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0078)
| Name |
Luteolin
|
||||
|---|---|---|---|---|---|
| Synonyms |
luteolin; 491-70-3; Digitoflavone; Luteolol; 3',4',5,7-Tetrahydroxyflavone; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Flacitran; Luteoline; Salifazide; Weld Lake; Yama kariyasu; Cyanidenon 1470; 5,7,3',4'-Tetrahydroxyflavone; C.I. Natural Yellow 2; Bismite; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one; Cyanidenon-1470; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; Daphneflavonol; Flavopurpol; CCRIS 3790; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone; BRN 0292084; UNII-KUX1ZNC9J2; KUX1ZNC9J2; EINECS 207-741-0; CHEBI:15864; C.I. 75590; FLAVONE, 3',4',5,7-TETRAHYDROXY-; MFCD00017309; CHEMBL151; DTXSID4074988; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-chromenone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one; 1318-21-4; SMR000326896; 7-Tetrahydroxyflavone; SR-01000779333; Argemexitin; Lutl; 4dew; 4dgn; 4hkn; Luteolin,(S); 3',4',5,7-Tetrahydroxy-Flavone; LU2; Prestwick_122; LUTEOLIN [INCI]; LUTEOLIN [MI]; Prestwick0_000870; Prestwick1_000870; Prestwick2_000870; Prestwick3_000870; LUTEOLIN [WHO-DD]; BIDD:PXR0059; Lopac0_000660; Oprea1_849964; SCHEMBL20426; BSPBio_000919; Luteolin, analytical standard; MLS000697655; MLS000860038; MLS002154043; MLS006011917; BIDD:ER0122; SPBio_002840; BDBM7459; BPBio1_001011; GTPL5215; MEGxp0_000143; DTXCID6040668; ACon1_000223; cid_5280445; HMS1570N21; HMS2097N21; HMS2220C06; HMS3356L02; HMS3561N09; HMS3649N21; HMS3656A05; HMS3714N21; Luteolin, >=99.0% (TLC); BCP03511; HY-N0162; TNP00073; Luteolin, >=98% (TLC), powder; BBL027837; LMPK12110006; s2320; STK801923; AKOS002140588; AC-1125; BCP9000865; CCG-208309; CS-4611; DB15584; KS-5202; Luteolin 100 microg/mL in Acetonitrile; SMP2_000042; NCGC00016467-01; NCGC00016467-02; NCGC00016467-03; NCGC00016467-04; NCGC00016467-05; NCGC00016467-06; NCGC00016467-07; NCGC00016467-08; NCGC00016467-21; NCGC00142375-01; NCGC00142375-02; NCGC00142375-03; NCGC00179375-01; NCGC00179375-02; CAS-491-70-3; SY030155; BCP0726000198; FT-0600053; SW196433-3; T2682; C01514; L 9283; S00110; EN300-1659559; A827664; Luteolin, primary pharmaceutical reference standard; Q415011; Q-100551; SR-01000779333-4; SR-01000779333-5; SR-01000779333-7; BRD-K05236810-001-05-9; 23A002A4-B47B-46CD-848C-65042EACF3FF; NCGC00142375-01,NCGC00142375-02; Z1741977179; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-benzopyrone-4-one; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one #; 4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C15H10O6
|
||||
| IUPAC Name |
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
|
||||
| Canonical SMILES |
C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
|
||||
| InChI |
InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
|
||||
| InChIKey |
IQPNAANSBPBGFQ-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Prostaglandin G/H synthase 2 (PTGS2)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Marker | ||||
| Responsed Disease | Ischemia/reperfusion injury | ICD-11: DB98 | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | CHO-S/H9C2 cells | Normal | Cricetulus griseus | CVCL_A0TS | |
| In Vivo Model |
In this study, 30 male Sprague Dawley rats (325-375 g) anesthetized using pentobarbital (1.5 g/kg, i.p.) were used for heart infarct studies,Western blot analysis, and qPCR. The isolated hearts were perfused in a Langendorff system. A water-filled latex balloon was inserted into the left ventricle cavity via mitral valve and linked to a physiological pressure transducer (AD Instruments, MLT884) for continuous monitoring of left ventricular systolic pressure (LVSP) and end diastolic pressure (LVEDP). Left ventricular developed pressure (LVDP) was calculated as the difference between LVSP and LVEDP (LVDP = LVSP-LVEDP). Measurements were recorded using PowerLab system and Chart 8 software (ADInstrument, Bella Vista, New South Wales, Australia). The hearts were stable for 30 min, and then subjected to 45 min of global ischemia by halting perfusion, followed by 1 h of reperfusion with Krebs-Henseleit (KH) bicarbonate buffer gassed with 95% O2, 5% CO2 at 37 (pH 7.4). The infarcted myocardium was measured using triphenyltetrazolium chloride(TTC, 25 mg/mL) staining. The KH buffer containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO 31.3 mM CaCl2, and 11 mM glucose was filtered through a 0.22 uM pore before use.
Click to Show/Hide
|
||||
| Response regulation | Baicalein and luteolin protected cardiomyocytes against ferroptosis caused by ferroptosis inducers and I/R. Moreover, both baicalein and luteolin decreased ROS and malondialdehyde (MDA) generation and the protein levels of ferroptosis markers, and restored Glutathione peroxidase 4 (GPX4) protein levels in cardiomyocytes reduced by ferroptosis inducers. Baicalein and luteolin reduced the ischemia/reperfusion-induced myocardium infarction and decreased the levels of Acsl4 and Ptgs2 mRNA. | ||||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Ischemia/reperfusion injury | ICD-11: DB98 | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | CHO-S/H9C2 cells | Normal | Cricetulus griseus | CVCL_A0TS | |
| In Vivo Model |
In this study, 30 male Sprague Dawley rats (325-375 g) anesthetized using pentobarbital (1.5 g/kg, i.p.) were used for heart infarct studies,Western blot analysis, and qPCR. The isolated hearts were perfused in a Langendorff system. A water-filled latex balloon was inserted into the left ventricle cavity via mitral valve and linked to a physiological pressure transducer (AD Instruments, MLT884) for continuous monitoring of left ventricular systolic pressure (LVSP) and end diastolic pressure (LVEDP). Left ventricular developed pressure (LVDP) was calculated as the difference between LVSP and LVEDP (LVDP = LVSP-LVEDP). Measurements were recorded using PowerLab system and Chart 8 software (ADInstrument, Bella Vista, New South Wales, Australia). The hearts were stable for 30 min, and then subjected to 45 min of global ischemia by halting perfusion, followed by 1 h of reperfusion with Krebs-Henseleit (KH) bicarbonate buffer gassed with 95% O2, 5% CO2 at 37 (pH 7.4). The infarcted myocardium was measured using triphenyltetrazolium chloride(TTC, 25 mg/mL) staining. The KH buffer containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO 31.3 mM CaCl2, and 11 mM glucose was filtered through a 0.22 uM pore before use.
Click to Show/Hide
|
||||
| Response regulation | Baicalein and luteolin protected cardiomyocytes against ferroptosis caused by ferroptosis inducers and I/R. Moreover, both baicalein and luteolin decreased ROS and malondialdehyde (MDA) generation and the protein levels of ferroptosis markers, and restored Glutathione peroxidase 4 (GPX4) protein levels in cardiomyocytes reduced by ferroptosis inducers. Baicalein and luteolin reduced the ischemia/reperfusion-induced myocardium infarction and decreased the levels of Acsl4 and Ptgs2 mRNA. | ||||
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Driver | ||||
| Responsed Disease | Ischemia/reperfusion injury | ICD-11: DB98 | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | CHO-S/H9C2 cells | Normal | Cricetulus griseus | CVCL_A0TS | |
| In Vivo Model |
In this study, 30 male Sprague Dawley rats (325-375 g) anesthetized using pentobarbital (1.5 g/kg, i.p.) were used for heart infarct studies,Western blot analysis, and qPCR. The isolated hearts were perfused in a Langendorff system. A water-filled latex balloon was inserted into the left ventricle cavity via mitral valve and linked to a physiological pressure transducer (AD Instruments, MLT884) for continuous monitoring of left ventricular systolic pressure (LVSP) and end diastolic pressure (LVEDP). Left ventricular developed pressure (LVDP) was calculated as the difference between LVSP and LVEDP (LVDP = LVSP-LVEDP). Measurements were recorded using PowerLab system and Chart 8 software (ADInstrument, Bella Vista, New South Wales, Australia). The hearts were stable for 30 min, and then subjected to 45 min of global ischemia by halting perfusion, followed by 1 h of reperfusion with Krebs-Henseleit (KH) bicarbonate buffer gassed with 95% O2, 5% CO2 at 37 (pH 7.4). The infarcted myocardium was measured using triphenyltetrazolium chloride(TTC, 25 mg/mL) staining. The KH buffer containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO 31.3 mM CaCl2, and 11 mM glucose was filtered through a 0.22 uM pore before use.
Click to Show/Hide
|
||||
| Response regulation | Baicalein and luteolin protected cardiomyocytes against ferroptosis caused by ferroptosis inducers and I/R. Moreover, both baicalein and luteolin decreased ROS and malondialdehyde (MDA) generation and the protein levels of ferroptosis markers, and restored Glutathione peroxidase 4 (GPX4) protein levels in cardiomyocytes reduced by ferroptosis inducers. baicalein and luteolin reduced the ischemia/reperfusion-induced myocardium infarction and decreased the levels of Acsl4 and Ptgs2 mRNA. | ||||